Gastrin-17 Combined with CEA, CA12-5 and CA19-9 Improves the Sensitivity for the Diagnosis of Gastric Cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–542. doi:10.1016/j.cgh.2019.07.045
   PubMed Web of Science ®Google Scholar
• Agnes A, Biondi A, Laurino A, et al. Global updates in the treatment of gastric cancer: a systematic review. Part 1: staging, classification and surgical treatment. Updates Surg. 2020;72(2):341–353. doi:10.1007/s13304-020-00736-3
   PubMed Web of Science ®Google Scholar
• Feng F, Tian Y, Xu G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017;17(1):737. doi:10.1186/s12885-017-3738-y
   PubMed Web of Science ®Google Scholar
• Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2009;15(1):1–16. doi:10.3748/wjg.15.1
   PubMed Web of Science ®Google Scholar
• Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54(6):764–768. doi:10.1136/gut.2004.055400
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric cancer screening by combined assay for serum Anti-Helicobacter pylori IgG antibody and serum pepsinogen levels – the ABC method. Digestion. 2016;93(1):13–18. doi:10.1159/000441742
   PubMed Web of Science ®Google Scholar
• He CZ, Zhang KH, Li Q, et al. Combined use of AFP, CEA, CA125 and CA19-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13(1):87. doi:10.1186/1471-230X-13-87
   PubMed Web of Science ®Google Scholar
• Lin Z, Bian H, Chen C, Chen W, Li Q. Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer. J Gastrointest Oncol. 2021;12(3):1042–1048. doi:10.21037/jgo-21-254
   PubMed Web of Science ®Google Scholar
• Li Y, Yang Y, Lu M, et al. Predictive value of serum CEA, CA19-9 and CA72-4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology. 2011;58(112):2166–2170.
   PubMedGoogle Scholar
• Cui W, Lu X, Zheng S, et al. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Clin Lab. 2012;58(5–6):419–426.
   PubMed Web of Science ®Google Scholar
• Yang AP, Liu J, Lei HY, et al. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer. Clin Chim Acta. 2014;437:183–186. doi:10.1016/j.cca.2014.07.034
   PubMed Web of Science ®Google Scholar
• Maddalo G, Spolverato Y, Rugge M, et al. Gastrin: from pathophysiology to cancer prevention and treatment. Eur J Cancer Prev. 2014;23(4):258–263. doi:10.1097/CEJ.0000000000000008
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Chang W, Jin G, et al. Gastrin and upper GI cancers. Curr Opin Pharmacol. 2016;31:31–37. doi:10.1016/j.coph.2016.08.013
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu Z, Liu Z, et al. The value of detecting pepsinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gastric cancer. J Int Med Res. 2020;48(3):300060520914826.
   PubMed Web of Science ®Google Scholar
• Murphy G, Abnet CC, Choo-Wosoba H, et al. Serum gastrin and cholecystokinin are associated with subsequent development of gastric cancer in a prospective cohort of Finnish smokers. Int J Epidemiol. 2017;46(3):914–923. doi:10.1093/ije/dyx030
   PubMed Web of Science ®Google Scholar
• Tu H, Sun L, Dong X, et al. A serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: a multi-phase study. Am J Gastroenterol. 2017;112(5):704–715. doi:10.1038/ajg.2017.55
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu Z, Liu Z, et al. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer. J Int Med Res. 2020;48(3):300060520914826.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Rodríguez-Enríquez S, Pacheco-Velázquez SC, Gallardo-Pérez JC, et al. Multi-biomarker pattern for tumor identification and prognosis. J Cell Biochem. 2011;112(10):2703–2715. doi:10.1002/jcb.23224
   PubMed Web of Science ®Google Scholar
• Liang Y, Wang W, Fang C, et al. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer. Oncotarget. 2016;7(31):49565–49573. doi:10.18632/oncotarget.10391
   PubMedGoogle Scholar
• Basbug M, Arikanoglu Z, Bulbuller N, et al. Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepatogastroenterology. 2011;58(106):400–405.
   PubMedGoogle Scholar
• Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 1999;10(Suppl 4):145–149. doi:10.1093/annonc/10.suppl_4.S145
   PubMed Web of Science ®Google Scholar
• Klug TL, Bast RC Jr, Niloff JM, et al. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984;44(3):1048–1053.
   PubMed Web of Science ®Google Scholar
• Wang W, Chen XL, Zhao SY, et al. Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma. Oncotarget. 2016;7(23):35423–35436. doi:10.18632/oncotarget.8770
   PubMedGoogle Scholar
• Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26–33. doi:10.1007/s10120-013-0259-5
   PubMed Web of Science ®Google Scholar
• Väänänen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric istology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. 2003;15(8):885–891. doi:10.1097/00042737-200308000-00009
   PubMed Web of Science ®Google Scholar
• Soran A, Aslar AK, Cöl C. Are preoperative serum gastrin levels related to resectability and survival in gastric cancer? Int J Clin Pract. 2000;54(10):652–653.
   PubMed Web of Science ®Google Scholar
• Rakic S, Milicevic MN. Serum gastrin levels in patients with intestinal and diffuse type of gastric cancer. Br J Cancer. 1991;64(6):1189. doi:10.1038/bjc.1991.489
   PubMed Web of Science ®Google Scholar
• Kang JM, Kim N, Yoo JY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter. 2008;13(2):146–156. doi:10.1111/j.1523-5378.2008.00592.x
   PubMed Web of Science ®Google Scholar
• Mansour-Ghanaei F, Joukar F, Rajpout Y, et al. Screening of precancerous gastric lesions by serum pepsinogen, Gastrin-17, anti-helicobacter pylori and anti- caga Antibodies in dyspeptic patients over 50 years old in Guilan Province, North of Iran. Asian Pac J Cancer Prev. 2014;15(18):7635–7638. doi:10.7314/APJCP.2014.15.18.7635
   PubMedGoogle Scholar
• Zhao WX, Liu ZF, Li XL, et al. Correlations of serum homocysteine, VEGF and gastrin 17 with gastric cancer and precancerous lesions. Eur Rev Med Pharmacol Sci. 2019;23(10):4192–4198.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang GX, Wang HG, et al. The value of detecting pepsinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gastric cancer. Neoplasma. 2019;66(4):637–640. doi:10.4149/neo_2018_180825N647
   PubMed Web of Science ®Google Scholar
• Gadde R, Tamariz L, Hanna M, et al. Metastatic gastric cancer (MGC) patients: can we improve survival by metastasectomy? A systematic review and meta-analysis. J Surg Oncol. 2015;112(1):38–45. doi:10.1002/jso.23945
   PubMed Web of Science ®Google Scholar
• Chen C, Chen Q, Zhao Q, et al. Value of combined detection of serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the diagnosis of gastric cancer. Ann Clin Lab Sci. 2017;47(3):260–263.
   PubMed Web of Science ®Google Scholar